1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Denmark >
  5. Ensoma Acquires Twelve Bio

M&A Deal Summary

Ensoma Acquires Twelve Bio

On January 5, 2023, Ensoma acquired life science company Twelve Bio

Acquisition Highlights
  • This is Ensoma’s 1st transaction in the Life Science sector.
  • This is Ensoma’s 1st transaction in Denmark.

M&A Deal Summary
Date 2023-01-05
Target Twelve Bio
Sector Life Science
Buyer(s) Ensoma
Deal Type Add-on Acquisition

Target

Twelve Bio

Copenhagen, Denmark
Twelve Bio is a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas technology. The company has advanced foundational insights from X-ray crystallography and cryogenic electron microscopy to further engineer and evolve CRISPR-Cas12a into wholly novel sequences with unique properties useful for a range of DNA editing strategies. Twelve Bio was formed in 2019 and is based in Copenhagen, Denmark.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Ensoma

Boston, Massachusetts, United States
Category Company
Sector Life Science
DESCRIPTION

Ensoma is a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system. The company’s Engenious platform combines innovative delivery technology with the full DNA editing toolkit to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Denmark M&A 1 of 1
Year: 2023 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal